-+ 0.00%
-+ 0.00%
-+ 0.00%

Annexon Inc. Completes Enrollment for Pivotal Phase 3 Trial of Vonaprument, Aiming to Become First Approved Treatment for Dry AMD with Geographic Atrophy in U.S. and Europe

Reuters·07/24/2025 11:00:52

Please log in to view news